Quick Answer
SAB Biotherapeutics, Inc. reported Diluted EPS of $0.79 per share (loss) for fiscal year 2025.
SAB Biotherapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.79 | +78.5% |
| 2024 | -$3.68 | +51.8% |
| 2023 | -$7.64 | -77.3% |
| 2022 | -$4.31 | -584.1% |
| 2021 | -$0.63 | -185.1% |
| 2020 | $0.74 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | +81.2% | +80.7% |
| June 30, 2025 | -$1.09 | -38.0% | -94.6% |
| March 31, 2025 | -$0.56 | -3.7% | +50.0% |
| September 30, 2024 | -$1.12 | -15.5% | -41.8% |
| June 30, 2024 | -$0.79 | +41.9% | -46.3% |
| March 31, 2024 | -$0.54 | +63.0% | +44.3% |
| September 30, 2023 | -$0.97 | -506.2% | +28.7% |
| June 30, 2023 | -$1.36 | -1136.4% | +6.8% |
- SAB Biotherapeutics, Inc. showed an increase of +78.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s diluted eps has declined by 206.8% (from $0.74 per share to $0.79 per share (loss)).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: